Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Imatinib was administered to newly diagnosed patients with chronic-phase myelogenous leukemia at a dose (800 mg daily) double what is commonly prescribed. Cytogenetic and molecular responses were significantly better than observed in an historical cohort of similar patients treated with 400 mg daily.

High-Dose Imatinib Mesylate (Gleevec®) for CML